


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 16 Jan 2017
Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors
Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors
HSMN NewsFeed - 16 Jan 2017
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
HSMN NewsFeed - 13 Jan 2017
Merck KGaA, Darmstadt, Germany, and Palantir Launch New Healthcare Acceleration Partnership
Merck KGaA, Darmstadt, Germany, and Palantir Launch New Healthcare Acceleration Partnership
HSMN NewsFeed - 9 Jan 2017
Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO
Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO
HSMN NewsFeed - 9 Jan 2017
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
HSMN NewsFeed - 6 Jan 2017
Viking Therapeutics Announces Senior Level Appointments to Management Team
Viking Therapeutics Announces Senior Level Appointments to Management Team
HSMN NewsFeed - 6 Jan 2017
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
HSMN NewsFeed - 4 Jan 2017
Vtesse Announces Appointment of Jason Meyenburg as Chief Commercial Officer
Vtesse Announces Appointment of Jason Meyenburg as Chief Commercial Officer
HSMN NewsFeed - 4 Jan 2017
Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
HSMN NewsFeed - 3 Jan 2017
Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer
Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer
HSMN NewsFeed - 3 Jan 2017
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
HSMN NewsFeed - 3 Jan 2017
Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc
Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc
HSMN NewsFeed - 2 Jan 2017
BiondVax Receives $US 2.8 Million Investment From Angels High Tech Investments Ltd.
BiondVax Receives $US 2.8 Million Investment From Angels High Tech Investments Ltd.
HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
HSMN NewsFeed - 28 Dec 2016
Concordia International Corp. Announces Leadership Transition at International Segment
Concordia International Corp. Announces Leadership Transition at International Segment
HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
HSMN NewsFeed - 27 Dec 2016
Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene(R) Mist
Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene(R) Mist
HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
HSMN NewsFeed - 22 Dec 2016
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
HSMN NewsFeed - 19 Dec 2016
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
HSMN NewsFeed - 16 Dec 2016
Antibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement
Antibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement
HSMN NewsFeed - 15 Dec 2016
ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors
ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors
HSMN NewsFeed - 14 Dec 2016
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO
HSMN NewsFeed - 9 Dec 2016
Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
HSMN NewsFeed - 8 Dec 2016
Agenovir Appoints Industry Veteran Dirk Thye, M.D. As Chief Executive Officer
Agenovir Appoints Industry Veteran Dirk Thye, M.D. As Chief Executive Officer
HSMN NewsFeed - 7 Dec 2016
Neovacs obtains FDA “Fast Track” designation for IFNα Kinoid in Lupus (SLE)
Neovacs obtains FDA “Fast Track” designation for IFNα Kinoid in Lupus (SLE)
HSMN NewsFeed - 6 Dec 2016
Theresa LaVallee, Ph.D., Joins Celldex Therapeutics’ Senior Management Team
Theresa LaVallee, Ph.D., Joins Celldex Therapeutics’ Senior Management Team
HSMN NewsFeed - 2 Dec 2016
Allergan Announces Settlement of a DELZICOL(R) (mesalamine) Patent Litigation
Allergan Announces Settlement of a DELZICOL(R) (mesalamine) Patent Litigation
HSMN NewsFeed - 29 Nov 2016
Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer
Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer
HSMN NewsFeed - 29 Nov 2016
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 29 Nov 2016
OxThera Raises EUR 32 Million to Complete Development of Oxabact(R) for Treatment of Primary Hyperoxaluria
OxThera Raises EUR 32 Million to Complete Development of Oxabact(R) for Treatment of Primary Hyperoxaluria
HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Conditional Approval from the European Commission to Treat Multiple Myeloma
HSMN NewsFeed - 28 Nov 2016
Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer
Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer
